Merck Sues Cobalt Over ANDA For Generic Fosamax

Law360, New York (June 30, 2005, 12:00 AM EDT) -- Drug maker Merck & Co. has sued Canada’s Cobalt Pharmaceuticals over its plans to make a generic version of its best-selling osteoporosis treatment Fosamax.

The lawsuit, filed in the U.S. District Court for the District of Delaware, accuses Cobalt of infringing eight patents that are set to expire between 2012 and 2018.

Merck filed the complaint after receiving notice that Cobalt had filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration for 35, 40 and 70 mg alendronate sodium tablets, the...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.